FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2725478873> ?p ?o ?g. }

• W2725478873 endingPage "5387" @default.
• W2725478873 startingPage "5387" @default.
• W2725478873 abstract "Abstract Background and objective. Anthracycline-induced cardiotoxicity is a major issue in the treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL). The use of non pegylated liposomal doxorubicin (Myocet®)has been associated with less cardiotoxicity as compared to conventional doxorubicin in breast cancer, but its benefit in DLBCL has been investigated mostly in retrospective and single-arm prospective studies. The objective of this study was to evaluate the benefit, in terms of cardiac toxicity, of the substitution of conventional doxorubicin as part of R-CHOP therapy by the non pegylated liposomal doxorubicin (Myocet®, R-COMP arm) in older patients (≥60 years) with de novo DLBCL or grade 3b follicular lymphoma (FL). Methods. This is a prospective randomized phase 2 trial (ClinicalTrials.gov Identifier: NCT02012088) of newly diagnosed patients with DLBCL or grade 3b FL ≥60 years old with baseline left ventricular ejection fraction (LVEF) > 55%. Patients were randomized to R-COMP or R-CHOP (in both cases every 21 days for a total of 6 cycles, with a dose of conventional doxorubicin or Myocet® of 50 mg/m2/cycle). The primary end-point was to evaluate the differences in subclinical cardiotoxicity between the two arms of treatment, defined by a decrease in LVEF to ≤ 55% at the end of treatment (measured by echocardiography at 1 and 4 months after the last cycle of chemotherapy). Secondary objectives were efficacy, safety and differences in the variations of cardiac biomarkers (troponin and N-terminal pro B-type natriuretic peptide [NT-proBNP]) through therapy in both arms of treatment. Results. Patient characteristics. A total of 91 patients from 15 Spanish hospitals were included, with a median age of 75 years (range 60-86), 49 (54%) were females. ECOG performance status was 2 in 15 (16%), stage III-IV in 68 (76%) and IPI 3-5 in 56 (63%). A total of 46 patients received R-COMP while 45 were treated with R-CHOP, without significant differences between arms regarding baseline characteristics. Subclinical cardio-toxicity: No differences between arms were observed in the number of patients with LVEF ≤55% determined at the end of treatment or at 4 months (6 [15%] in those treated with R-COMP and 5 [14%] in the R-CHOP arm, p=0.966). However, a higher number of patients in R-CHOP arm increased troponin levels at cycle 6 of treatment (17 out of 24 evaluable patients [71%] in R-COMP group vs. 25 out of 25 evaluable patients [100%] in R-CHOP group, p=0.004) or at the end-of-treatment visit (13 out of 21 evaluable patients [62%] in R-COMP group vs. 20 out of 23 evaluable patients [87%] in R-CHOP group, p=0.05). No differences between both groups were observed in variations of NT-proBNP levels through treatment period and follow-up. Serious adverse events (SAEs): With a median follow-up of 16 months (range 0.7-34), a total of 59 SAEs were reported in 37 patients (39 in 21 patients from R-COMP group and 20 in 16 patients from R-CHOP group), including 18 infections (12 in R-COMP and 6 in R-CHOP), and 14 episodes of febrile neutropenia (9 in R-COMP and 5 in R-CHOP). Four patients showed cardiovascular events: atrial fibrillation (n=1, R-COMP group), supraventricular tachycardia (n=2, R-CHOP group), and myocardial infarction (n=1, R-CHOP group). Efficacy: Overall response (OR) and complete remission (CR) were observed in 72 (96%) and 54 (72%) patients, respectively, without differences between R-COMP group (OR and CR rates of 97% and 72%) and R-CHOP group (OR and CR rates of 94% and 72%) (p=0.775). Conclusions. R-COMP is a feasible immunochemotherapy schedule for patients with de novo DLBCL older than 60 years. However, in our series, the use of non-pegylated doxorubicin instead of conventional doxorubicin was not associated with less decrease in LVEF measured by echocardiography, although the differences in troponin levels merits the need for further evaluation with a higher number of evaluable patients and longer follow-up. Disclosures Sancho: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celltrion, Inc: Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees. González-Barca:Roche: Honoraria; Gilead: Honoraria; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees. Martín:Janssen: Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Sevier: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W2725478873 created "2017-07-14" @default.
• W2725478873 creator A5004401859 @default.
• W2725478873 creator A5013472737 @default.
• W2725478873 creator A5015203310 @default.
• W2725478873 creator A5018326998 @default.
• W2725478873 creator A5026525202 @default.
• W2725478873 creator A5030257131 @default.
• W2725478873 creator A5041947496 @default.
• W2725478873 creator A5047866471 @default.
• W2725478873 creator A5048566051 @default.
• W2725478873 creator A5052329555 @default.
• W2725478873 creator A5054979681 @default.
• W2725478873 creator A5055303369 @default.
• W2725478873 creator A5065316351 @default.
• W2725478873 creator A5067708412 @default.
• W2725478873 creator A5070245879 @default.
• W2725478873 creator A5071493927 @default.
• W2725478873 creator A5078500466 @default.
• W2725478873 creator A5083191976 @default.
• W2725478873 creator A5089316426 @default.
• W2725478873 date "2016-12-02" @default.
• W2725478873 modified "2023-10-09" @default.
• W2725478873 title "R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo" @default.
• W2725478873 doi "https://doi.org/10.1182/blood.v128.22.5387.5387" @default.
• W2725478873 hasPublicationYear "2016" @default.
• W2725478873 type Work @default.
• W2725478873 sameAs 2725478873 @default.
• W2725478873 citedByCount "0" @default.
• W2725478873 crossrefType "journal-article" @default.
• W2725478873 hasAuthorship W2725478873A5004401859 @default.
• W2725478873 hasAuthorship W2725478873A5013472737 @default.
• W2725478873 hasAuthorship W2725478873A5015203310 @default.
• W2725478873 hasAuthorship W2725478873A5018326998 @default.
• W2725478873 hasAuthorship W2725478873A5026525202 @default.
• W2725478873 hasAuthorship W2725478873A5030257131 @default.
• W2725478873 hasAuthorship W2725478873A5041947496 @default.
• W2725478873 hasAuthorship W2725478873A5047866471 @default.
• W2725478873 hasAuthorship W2725478873A5048566051 @default.
• W2725478873 hasAuthorship W2725478873A5052329555 @default.
• W2725478873 hasAuthorship W2725478873A5054979681 @default.
• W2725478873 hasAuthorship W2725478873A5055303369 @default.
• W2725478873 hasAuthorship W2725478873A5065316351 @default.
• W2725478873 hasAuthorship W2725478873A5067708412 @default.
• W2725478873 hasAuthorship W2725478873A5070245879 @default.
• W2725478873 hasAuthorship W2725478873A5071493927 @default.
• W2725478873 hasAuthorship W2725478873A5078500466 @default.
• W2725478873 hasAuthorship W2725478873A5083191976 @default.
• W2725478873 hasAuthorship W2725478873A5089316426 @default.
• W2725478873 hasConcept C121608353 @default.
• W2725478873 hasConcept C126322002 @default.
• W2725478873 hasConcept C141071460 @default.
• W2725478873 hasConcept C143998085 @default.
• W2725478873 hasConcept C168563851 @default.
• W2725478873 hasConcept C203092338 @default.
• W2725478873 hasConcept C2776694085 @default.
• W2725478873 hasConcept C2776802502 @default.
• W2725478873 hasConcept C2778198053 @default.
• W2725478873 hasConcept C2778233292 @default.
• W2725478873 hasConcept C2778559949 @default.
• W2725478873 hasConcept C2781303535 @default.
• W2725478873 hasConcept C530470458 @default.
• W2725478873 hasConcept C71924100 @default.
• W2725478873 hasConcept C78085059 @default.
• W2725478873 hasConcept C90924648 @default.
• W2725478873 hasConceptScore W2725478873C121608353 @default.
• W2725478873 hasConceptScore W2725478873C126322002 @default.
• W2725478873 hasConceptScore W2725478873C141071460 @default.
• W2725478873 hasConceptScore W2725478873C143998085 @default.
• W2725478873 hasConceptScore W2725478873C168563851 @default.
• W2725478873 hasConceptScore W2725478873C203092338 @default.
• W2725478873 hasConceptScore W2725478873C2776694085 @default.
• W2725478873 hasConceptScore W2725478873C2776802502 @default.
• W2725478873 hasConceptScore W2725478873C2778198053 @default.
• W2725478873 hasConceptScore W2725478873C2778233292 @default.
• W2725478873 hasConceptScore W2725478873C2778559949 @default.
• W2725478873 hasConceptScore W2725478873C2781303535 @default.
• W2725478873 hasConceptScore W2725478873C530470458 @default.
• W2725478873 hasConceptScore W2725478873C71924100 @default.
• W2725478873 hasConceptScore W2725478873C78085059 @default.
• W2725478873 hasConceptScore W2725478873C90924648 @default.
• W2725478873 hasIssue "22" @default.
• W2725478873 hasLocation W27254788731 @default.
• W2725478873 hasOpenAccess W2725478873 @default.
• W2725478873 hasPrimaryLocation W27254788731 @default.
• W2725478873 hasRelatedWork W19039903 @default.
• W2725478873 hasRelatedWork W196094705 @default.
• W2725478873 hasRelatedWork W2304617849 @default.
• W2725478873 hasRelatedWork W2469557391 @default.
• W2725478873 hasRelatedWork W2514057718 @default.
• W2725478873 hasRelatedWork W2546628905 @default.
• W2725478873 hasRelatedWork W2580415066 @default.
• W2725478873 hasRelatedWork W2584296960 @default.
• W2725478873 hasRelatedWork W2586342709 @default.
• W2725478873 hasRelatedWork W2586442817 @default.
• W2725478873 hasRelatedWork W2592055730 @default.
• W2725478873 hasRelatedWork W277399393 @default.
• W2725478873 hasRelatedWork W2906135263 @default.

• next